Published in Science · View the paper (DOI)
A new clinical study found that genetic defects in mismatch repair (MMR) pathway tumors can indicate successful response to PD-1 blockade immunotherapy. The trial showed pembrolizumab controlled disease in 66 patients and caused complete tumor disappearance in 18, with no recurrence for an average of 8.3 months.
Coverage from 2 institutions
- Genetic mutations predict patient response to immunotherapy American Association for the Advancement of Science (AAAS) · Jun 8, 2017 · first to report
- Flaws in a tumor's genetic mending kit drive treatment response to immunotherapy Johns Hopkins Medicine · Jun 9, 2017